Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMBRKZ7)

Drug Name

CT1812 Drug Info

Synonyms

Elayta

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Sigma intracellular receptor 2 (TMEM97)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MIN-101	DMCJY35	Schizophrenia	6A20	Phase 3	[3]
Isoindoline derivative 5	DMIUTQW	N. A.	N. A.	Patented	[4]
Isoindoline derivative 3	DM2MYL9	N. A.	N. A.	Patented	[4]
Isoindoline derivative 4	DMP1NKI	N. A.	N. A.	Patented	[4]
Isoindoline derivative 2	DMTE0S3	N. A.	N. A.	Patented	[4]
Isoindoline derivative 1	DMD19QC	N. A.	N. A.	Patented	[4]
Benzamide derivative 9	DMVFSJZ	N. A.	N. A.	Patented	[4]
Benzamide derivative 10	DM9PKU2	N. A.	N. A.	Patented	[4]
PMID30185082-Compound-57	DMNDF1Z	N. A.	N. A.	Patented	[4]
PMID28051882-Compound-XIV	DM1RN89	N. A.	N. A.	Patented	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sigma intracellular receptor 2 (TMEM97)	TT9NXW4	SGMR2_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04735536) Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	The sigma-2 (-2) receptor: a review of recent patent applications: 2013-2018.Expert Opin Ther Pat. 2018 Sep;28(9):655-663.
5	Are sigma modulators an effective opportunity for cancer treatment A patent overview (1996-2016).Expert Opin Ther Pat. 2017 May;27(5):565-578.